Crossref
The FDA wants Bayesian trials, but who chooses the prior?
Significance · 08.06.2026 · 23 (4) · 4-5
DOI: 10.1093/jrssig/qmag038 ↗Kurz gefasst
Fachartikel in der Zeitschrift Significance, online erschienen am 08.06.2026. Verfasst von Lu Qian. Die Arbeit nennt 8 Literaturangaben.
Abstract (Originalsprache)
Earlier this year, new draft guidance from the US Food and Drug Administration encouraged the use of Bayesian methodology in clinical trials for new drugs. Lu (Maggie) Qian addresses some of the questions arising from this development
Zitieren
APA
Qian, L. (2026). The FDA wants Bayesian trials, but who chooses the prior?. Significance, 23(4), 4-5. https://doi.org/10.1093/jrssig/qmag038
Vancouver
Qian L. The FDA wants Bayesian trials, but who chooses the prior?. Significance. 2026;23(4):4-5. doi:10.1093/jrssig/qmag038
BibTeX
@article{Qian2026,
author = {Qian, Lu},
title = {The FDA wants Bayesian trials, but who chooses the prior?},
journal = {Significance},
year = {2026},
volume = {23},
number = {4},
pages = {4--5},
doi = {10.1093/jrssig/qmag038}
}
EUVIMED